Thank you very much for submitting your research manuscript for consideration to The EMBO Journal editorial office. All three referees judge the reported data as potentially interesting, but at the same time emphasize different aspects of the manuscript that needs at least some additional experimentation. Both refs#1 and #2 very much appreciate the cell culture aspect of the study, though requesting further elaboration on loss of alpha parvin function versus beta-parvin upregulation as well as relative importance of Rho versus Rac singaling. It becomes a bit more complicated looking at ref#3's report that also appreciates the cell culture part, but does have significant concerns related to the phenotypic description and understanding of the developmental defects in the heart. S/he still offers alternative approaches to circumvent transgenic cardiac rescue or indeed conditional deletion by assessing vSMC or pericyte phenotypes as early as E10.5. Overall though even this referee would not really oppose publication of the complementary cell culture part if the problems caused by the cardiac phenotype would be appropriately outlined and discussed in the more general context. All in all, and on condition that you carefully consider the points raised to extend and modify the manuscript, we would be willing to re-assess a thoroughly revised version of your work in the near future. I also have to remind you that it is EMBO_J policy to allow a single round of revisions only, which means that the final decision on acceptance or rejection will depend on the next and final version of your manuscript.
Referee #1 (Remarks to the Author):
This manuscript deals with the characterization of the alpha-parvin knockout mouse. These mice exhibit early embryonic lethality resulting from cardiovascular defects. The vascular defects are determined to be due to defects in pericyte migration resulting in incomplete coverage of the developing blood vessels. Cellular studies using pericyte/smooth muscle cell preparations suggest that the defect is the result of elevated Rho/ROCK signaling leading to increased myosin light chain phosphorylation and thus increased actomyosin contractility/decreased cell migration. These signaling defects appear to be restricted to the pericyte cell populations, as apv-/-fibroblasts do not exhibit these defects. Overall, this is an interesting and well-executed study that provides useful insight into the in vivo function of a-parvin, a focal adhesion and actin binding protein. However, there are several issues with the cellular studies that must be addressed, particularly the potential role of upregulated beta-parvin expression in the phenotypes observed. The relative importance of Rac versus Rho signaling also needs further analysis.
Specific points
1. It is not clear to me if the observed phenotypes are due to loss of a-pv or upregulation of b-parvin or a combination of both. While the whole embryo lysate does not demonstrate a significant change in the level of beta-parvin, the pericytes/SMCs have highly elevated levels. Thus the authors need to demonstrate more definitively (perhaps via SiRNA of a-vs. b-parvin in freshly isolated WT pericytes), that the increase in Rho is specific for a-parvin down regulation. Also, do the authors have any evidence that the level of b-parvin is upregulated in the pericytes in vivo? Given the whole embryo result, it is somewhat surprising that the derived fibroblasts (supp 6) also exhibit upregulation of b-parvin. Could this be an indirect consequence of tissue culture in both these cell types?
2. The movies of cell spreading and migration show a dramatically protrusive phenotype reminiscent of disregulated Rac rather than elevated Rho. This seems to contradict the biochemical Rho/Rac data (compare the FAK KO cells which are not at all protrusive, spread poorly and exhibit robust stress fibers). These data may not tell the whole story as only one time point is selected for these assays (furthermore 10 min is used for the primary cell isolates and 30 min, for the immortalized cells). Given the dynamic interplay between Rac and Rho during the first 90 min or so of cell spreading, a more detailed analysis of Rac and Rho activity during this time frame is needed to validate the mechanism proposed (The ROCK inhibitor data is not reliable here). Also it is important to confirm that both the primary and immortalized cells respond in the same way, since the defect in Rho signaling in the primaries appears to be minimal as compared to the immortalized cells. Fig 3F it looks as though the percentage of rescued primary cells is very low. It is hard for me to evaluate their phenotype from this one image and it would be very informative if movies of rescued primary and immortalized cells were provided. Indeed, it is not clear if the current movies are of primary or immortalized cells. Both should be provided along with their corresponding rescue.
Regarding the rescue experiments, in
4. The a-pv cells clearly have differences in random migration rates (movies) that may greatly impact the results of the chemotaxis assay (Fig 6B) . A chemokinesis analysis using the Boyden chamber assay should also be performed. Also, how do the rescued cells respond in the chemotaxis assay?
5. The data in Fig 7 relating to Ilk seems out of place (and overlaps substantially with the main conclusions of the supporting manuscript). These data should be removed from this manuscript. Also, unlike a-pv the amount of Ilk precipitated by b-pv seems to be way beyond stoichiometric ( Fig  7C) . Can the authors explain this?
Other points.
The switching back and forth between the use primary cell and immortalized cell populations (often within the same figure) is hard to follow at times-please be clearer.
The isolation of the pericyte/SMC population is quite crude. Contamination by other cell types could have a profound impact on the subsequent biochemical analyses. Also, once in culture, SMCs often change phenotype and signaling properties. The authors should provide more information regarding their validation protocols for these cells.
Referee #2 (Remarks to the Author):
This manuscript describes the cardiovascular defect in embryonic development of mice deficient for alpha-parvin, a member of the parvin/ILK/PINCH adaptor complex of integrins. Besides the defect in heart development, which has been described in other species before, the paper demonstrates convincingly a defect in mural cell recruitment of the developing vasculature. The authors show that the lack of alpha-parvin leads to the activation of RhoA, the RhoA effector ROCK and activation of Myosin II, with the consequence of hypercontraction of vSMC. These effects are accompanied by a defect in SMC migration, an effect that could be overcome by a ROCK inhbitor. Knocking down ILK in SMC also enhanced MLC phopsphorylation. Thus, the alpha-parvin-ILK complex restricts activation of MLC balancing contractility of vSMC.
The paper is very well written and the discussion reads very well and is convincing. The experiments are throughout of very high quality and the load of evidence impressive. It is interesting how selectively the lack of alpha-parvin seems to only effect some cell types and not others.
I have only some minor comments, which should be addressed before publication.
1) The evidence shown for normal spreading of alpha-pv-/-endothelial cells on FN in suppl. figure  2D is not too convincing. In the absence of quantification of this effect, this micrograph is not ideal. Are there better ones?
2) Figure 3A was not fully clear to me. What is the difference between b and c, or between e and f, are these just two different examples in each case (its all alphaSMA staining). These four micrographs are not very instructive, it would be helpful to see the nuclei, in order to understand the picture. Likewise, the bar is missing which would help to know the magnification.
3) The fact that beta-parvin becomes upregulated upon alpha-parvin ablation is very interesting. This would have opened the possibility that beta-parvin-ILK could be an activator of RhoA-ROCK, if the authors would not have shown that ILK knock down has a similar effect as alpha-parvin deficiency. This could be said even more explicitly at the end of the discussion. The manuscript on the role of parvin in SMC recruitment and function by Montanez et al complements the ILK story by the Adams lab. Especially the work preformed in cell culture nicely illustrates the importance of alpha parvin for Rho dependent contractility regulation. The weakness of the paper is the lack of cell specific deletion in vivo. Also the analysis of the vascular phenotype in vivo could be improved. The quality of SMC phenotype illustration is much better in the ILK paper and the authors should strive to provide similar quality and clarity in the imaging. Most problematic is the fact that the loss of alpha parvin leads to severe developmental defects of the heart. It is therefore very likely that most of the severe vascular phenotypes including lethality at E14.5 is a consequence of reduced cardiac function and hence reduced blood flow. This is not to say that alpha parvin will not have an important function in SMC, but it remains unclear exactly how important this is for the observed phenotype. In the absence of good imaging that would manifest the idea of profound hypercontractility of SMC in the vessels in vivo, the current data is not fully satisfactory.
It would greatly help to see better analysis of the vascular phenotype and better imaging of pericytes and vSMC to understand exactly what happens to these cells in vivo. From mechanistic perspective and mouse genetics, a cardiac rescue experiment by re-expressing a parvin under a cardiac promoter in a transgenic approach could be very helpful. That would be quicker than doing the whole story again using a conditional approach. Although the authors are reknown for the excellence in mouse transgenesis, I realize that the time required for such an approach exceeds the limit available for regular revision. Also the added time pressure imposed by the imminent publication of the ILK story makes this unattractive. One way to circumvent the problem is to investigate whether one can detect and nicely describe a vSMC or pericyte phenotype including hypercontractility and cell rounding, or cytoskelettal abnormalities as early as E10.5 when flow dependent remodelling defects are still of minor importance.
The addition of the cardiac data is important for the understanding of the vascular phenotype, but unfortunately for the authors raises more questions than it provides answers. Now they could either choose to investigate why cardiomyocytes fail to arrange the Z-disks appropriately, or to investigate in detail how alpha parvin regulates SMC function in vivo. Referee #1 (Remarks to the Author):
Overall, this is an interesting and well-executed study that provides useful insight into the in vivo function of a-parvin, a focal adhesion and actin binding protein. However, there are several issues with the cellular studies that must be addressed, particularly the potential role of upregulated betaparvin expression in the phenotypes observed. The relative importance of Rac versus Rho signaling also needs further analysis.
We carried out several additional experiments to clarify the contribution of β-pv upregulation as well as the roles of Rac and Rho signalling in α-pv -/-cells (see below).
Specific points:
There Figure  1D ). 2. The movies of cell spreading and migration show a dramatically protrusive phenotype reminiscent of disregulated Rac rather than elevated Rho. This seems to contradict the biochemical Rho/Rac data (compare the FAK KO cells which are not at all protrusive, spread poorly and exhibit robust stress fibers). These data may not tell the whole story as only one time point is selected for these assays (furthermore 10 min is used for the primary cell isolates and 30 min, for the immortalized cells). Given the dynamic interplay between Rac and Rho during the first 90 min or so of cell spreading, a more detailed analysis of Rac and Rho activity during this time frame is needed to validate the mechanism proposed (The ROCK inhibitor data is not reliable here). 
We agree with the reviewer that the highly dynamic and instable ruffle formation observed in α-pv

These results show that Rac activation occurs independently of α-pv, whereas RhoA activation depends on α-pv. These data together with the findings showing that inhibition of ROCK restores lamellipodia formation and Rac activity indicate that the primary defect in α-pv -/-cells is a dysregulation of RhoA-ROCK signalling. Importantly, RhoA-mediated inhibition of Rac is well documented (Tsuji et al, 2002; Worthylake et al, 2003). We have included this data in the new Supplementary Figures 7E-H and modified the text of the manuscript accordingly.
Also it is important to confirm that both the primary and immortalized cells respond in the same way, since the defect in Rho signaling in the primaries appears to be minimal as compared to the immortalized cells. Figure 7H ). Fig 3F it looks as though the percentage of rescued primary cells is very low. It is hard for me to evaluate their phenotype from this one image and it would be very informative if movies of rescued primary and immortalized cells were provided. Indeed, it is not clear if the current movies are of primary or immortalized cells. Both should be provided along with their corresponding rescue.
Unfortunately, we were unable to isolate primary SMA-positive cells in quantities required to perform a similar time course analysis of RhoA activity as with the immortalized cells. Importantly, however, the increase in RhoA activity in primary cells at 10 minutes is comparable to that observed in the immortalized cells (see new Supplementary
Regarding the rescue experiments, in
Unfortunately the transfection efficiency of primary SMA-positive cells is very low. This is typical for primary cell preparations, at least in our hands. To better illustrate the phenotype we have exchanged the image with a one that contains a higher percentage of rescued cells. In addition, we show the fluorescence channels separately to more clearly visualize the effect of α-pv reconstitution on the F-actin organization. We also show movies of immortalized cells (Supplementary movies 5, 6 and 7).
4. The a-pv cells clearly have differences in random migration rates (movies) that may greatly impact the results of the chemotaxis assay (Fig 6B) . A chemokinesis analysis using the Boyden chamber assay should also be performed. Also, how do the rescued cells respond in the chemotaxis assay? Figure 6B demonstrate that the α-pv -/-cells display an increased rate of random motility, and confirm our conclusion that α-pv is required for directional cell motility. The chemotaxis and chemokinesis assays were performed with primary cells. As mentioned in our response to the previous point, the transfection efficiency of primary cells is very low. Therefore we were unable to perform these assays with primary cells rescued with α-pv. Fig 7 relating to Ilk seems out of place (and overlaps substantially with the main conclusions of the supporting manuscript). These data should be removed from this manuscript. Also, unlike a-pv the amount of Ilk precipitated by b-pv seems to be way beyond stoichiometric ( Fig  7C) Other points:
We have performed chemokinesis assays with freshly isolated cells. The results, shown in the new
The data in
We modified the text and Figure legends to clarify which cells are used in each experiment.
The isolation of the pericyte/SMC population is quite crude. Contamination by other cell types could have a profound impact on the subsequent biochemical analyses. Also, once in culture, SMCs often change phenotype and signaling properties. The authors should provide more information regarding their validation protocols for these cells. Referee #2 (Remarks to the Author):
We agree that freshly isolated cells contain a minor population of non
We made several changes in the manuscript to strengthen out conclusions (see below).
1) The evidence shown for normal spreading of alpha-pv-/-endothelial cells on FN in suppl. figure  2D is not too convincing. In the absence of quantification of this effect, this micrograph is not ideal. Are there better ones? Figure 2E confirm that the endothelial cells spread normally also in the absence of α-pv.
We agree that the quality of this image is suboptimal. Due to the embryonic lethality of these mice, the isolation of primary endothelial cells is extremely difficult. To strengthen this point we have quantified the spreading of these cells. The results, shown in the new Supplementary
2) Figure 3A was not fully clear to me. What is the difference between b and c, or between e and f, are these just two different examples in each case (its all alphaSMA staining). These four micrographs are not very instructive, it would be helpful to see the nuclei, in order to understand the picture. Likewise, the bar is missing which would help to know the magnification. Figure 3A are higher magnifications of panels b and e, respectively. In order to avoid confusion we have removed panels b and c and included scale bars.
Panels c and f of
3) The fact that beta-parvin becomes upregulated upon alpha-parvin ablation is very interesting. This would have opened the possibility that beta-parvin-ILK could be an activator of RhoA-ROCK, if the authors would not have shown that ILK knock down has a similar effect as alpha-parvin deficiency. This could be said even more explicitly at the end of the discussion. We immortalized the cells using the SV40 T-large oncogene. We have included this information in the revised Material and methods section.
-How were the vSMC re-transfected?
We used Lipofectamine 2000 (Invitrogen) transfection reagent for transient transfections. We have included this information in the revised Material and methods section.
-The asterisk in figure 1B is missing The asterisk has been added. -legend of suppl. figure 2D describes CD31 staining as red, yet it is green in the figure.
This mistake has been corrected.
Referee #3 (Remarks to the Author):
The manuscript on the role of parvin in SMC recruitment and function by Montanez et al complements the ILK story by the Adams lab. Especially the work preformed in cell culture nicely illustrates the importance of alpha parvin for Rho dependent contractility regulation. The weakness of the paper is the lack of cell specific deletion in vivo. Also the analysis of the vascular phenotype in vivo could be improved. The quality of SMC phenotype illustration is much better in the ILK paper and the authors should strive to provide similar quality and clarity in the imaging. Most problematic is the fact that the loss of alpha parvin leads to severe developmental defects of the heart. It is therefore very likely that most of the severe vascular phenotypes including lethality at E14.5 is a consequence of reduced cardiac function and hence reduced blood flow. This is not to say that alpha parvin will not have an important function in SMC, but it remains unclear exactly how important this is for the observed phenotype. In the absence of good imaging that would manifest the idea of profound hypercontractility of SMC in the vessels in vivo, the current data is not fully satisfactory. Figure 4A) . We also included new stainings from pericytes (Supplementary Figure 6A) .
It would greatly help to see better analysis of the vascular phenotype and better imaging of pericytes and vSMC to understand exactly what happens to these cells in vivo. From mechanistic perspective and mouse genetics, a cardiac rescue experiment by re-expressing a parvin under a cardiac promoter in a transgenic approach could be very helpful. That would be quicker than doing the whole story again using a conditional approach. Although the authors are reknown for the excellence in mouse transgenesis, I realize that the time required for such an approach exceeds the limit available for regular revision. Also the added time pressure imposed by the imminent publication of the ILK story makes this unattractive. One way to circumvent the problem is to investigate whether one can detect and nicely describe a vSMC or pericyte phenotype including hypercontractility and cell rounding, or cytoskelettal abnormalities as early as E10.5 when flow dependent remodelling defects are still of minor importance. Figure 6B .
The addition of the cardiac data is important for the understanding of the vascular phenotype, but unfortunately for the authors raises more questions than it provides answers. Now they could either choose to investigate why cardiomyocytes fail to arrange the Z-disks appropriately, or to investigate in detail how alpha parvin regulates SMC function in vivo. 
